Silodosin Capsule
Product Images NDC 71335-3128

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Silodosin (NDC 71335-3128). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713353128)

Silodosin 8 mg capsules label showing the product name, strength, and quantity of 30 capsules. The label includes storage instructions, usage directions, a barcode, and repackager information from Bryant Ranch Prepack, Inc. It indicates oral use and is marked Rx only. Manufactured by Macleods Pharmaceuticals Ltd.*

FDA Label Image

689 (Silodosin Fig 02)

A line graph comparing changes from baseline in IPSS total score over time between placebo and Silodosin 8 mg groups. The x-axis represents days (baseline to day 84/LOCF), and the y-axis shows the change in score. The Silodosin group exhibits a greater decrease over time versus placebo, with statistical significance noted.*

FDA Label Image

444 (Silodosin Fig 1)

A line graph depicting silodosin concentration (ng/mL) in blood plasma over time (hours). The graph shows concentration increasing rapidly to a peak around 4 hours followed by a gradual decline through 24 hours, with error bars at each measurement point indicating variability.*

FDA Label Image

432 (Silodosin Fig 3)

A line graph comparing change from baseline in IPSS total score over time (days) between placebo and Silodosin 8 mg groups. The x-axis represents days, the y-axis shows change from baseline score. Silodosin 8 mg shows a greater reduction in IPSS total score over time compared to placebo, with statistical significance indicated.*

FDA Label Image

367 (Silodosin Fig 5)

A line graph comparing change from baseline in Qmax (mL/sec) over days between Silodosin 8 mg and placebo groups. The X-axis represents days (8, 1, 7, 14, 28, 84), and the Y-axis shows change from baseline in Qmax. Silodosin 8 mg shows a higher increase maintained over time compared to placebo, with statistical significance noted (p<0.05).*

FDA Label Image

239 (Silodosin Figure 4)

A line graph comparing change from baseline in Cmax (mU/sec) over days between Silodosin 8 mg and placebo groups. The x-axis represents study days, while the y-axis shows the change in Cmax. Silodosin shows a higher increase in Cmax compared to placebo, with statistical significance indicated at p<0.05.*

FDA Label Image

333 (Silodosin Str 01)

Chemical structure of silodosin, showing its molecular arrangement with benzene rings, amide, ether, and hydroxyl functional groups, consistent with the active ingredient in the Silodosin 8 mg oral capsule by Bryant Ranch Prepack.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.